The present invention relates to methods for detecting and quantifying intact protein-polynucleotide conjugate molecules in various sample matrices. In particular, the methods utilize triplex forming oligonucleotides in combination with protein-specific binding partners to respectively detect the polynucleotide and protein components of the conjugate molecules.

The present invention encompasses a diagnostic test and method to authenticate the veracity of a vaccine. The diagnostic test and method are especially useful in a specific and sensitive immunochromatographic assay, performable within about 15 minutes for the authentication, validation, and veracity of a vaccine, such as a COVID-19 vaccine, in a vial prior to administration to a human.

The present invention encompasses a diagnostic test and method to authenticate the veracity of a vaccine. The diagnostic test and method are especially useful in a specific and sensitive immunochromatographic assay, performable within about 15 minutes for the authentication, validation, and veracity of a vaccine, such as a COVID-19 vaccine, in a vial prior to administration to a human.

The present disclosure relates to a nanotechnology-based molecular sensing system, compositions, and methods that can be adapted to accurately detect a target gene in clinical samples, using anti-sense oligonucleotide capped plasmonic nanoparticles for selective detection of biological pathogens.

The present disclosure relates to a nanotechnology-based molecular sensing system, compositions, and methods that can be adapted to accurately detect a target gene in clinical samples, using anti-sense oligonucleotide capped plasmonic nanoparticles for selective detection of biological pathogens.

The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.

The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.

Methods and devices for ultrasensitive detection of target molecules (e.g., target nucleic acids or target proteins) from a biological sample are provided herein. In some embodiments, methods and devices enable ultrasensitive determination of the concentration of target molecules.

Methods and devices for ultrasensitive detection of target molecules (e.g., target nucleic acids or target proteins) from a biological sample are provided herein. In some embodiments, methods and devices enable ultrasensitive determination of the concentration of target molecules.

A method of detecting a target molecule, the method comprising: forming a complex of a target molecule, a capture oligonucleotide, an oligonucleotide primer, and a single-stranded circular DNA; performing a nucleic acid amplification reaction by rolling circle amplification based on the formation of the complex; and detecting amplified nucleic acid; wherein the single-stranded circular DNA contains a first region, and a second region linked to the 3′-side of the first region, and preferably further contains a sequence complementary to a detection reagent-binding sequence; the primer contains a first aptamer sequence which binds to the target molecule, and a sequence which is linked to the 3′-side of the first aptamer sequence and is complementary to the first region of the single-stranded circular DNA; and the capture oligonucleotide contains a sequence complementary to the second region of the single-stranded circular DNA, and a second aptamer sequence which is linked to the 3′-side of the sequence complementary to the second region and binds to the target molecule.